Share-Based Payments (Tables)

3 Months Ended

Jul. 31, 2019

Stock-based compensation expense was recognized as follows (table in thousands):



	Three Months Ended July 31,
	2019			2018
General and administrative	$	132		$	60
Sales and marketing	22			7
Research and development	3			4
Cost of oncology services	(26		)	12
Total stock-based compensation expense	$	131		$	83

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2019 and 2018 were as follows:

The Company’s stock options activity for the three months ended July 31, 2019 was as follows:



	Non- Employees		Directors and Employees		Total		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, May 1, 2019	50,000		2,373,626		2,423,626		$	3.19	5.3	$	14,557,000
Granted	—		—		—		—		—	—
Exercised	—		—		—		—		—	—
Forfeited	—		(40,000	)	(40,000	)	8.20
Canceled	—		(2,083	)	(2,083	)	11.50			—
Expired	(6,668	)	—		(6,668	)	12.24

Outstanding, July 31, 2019	43,332		2,331,543		2,374,875		3.08		4.9	$	8,836,000

Vested and expected to vest as of July 31, 2019	43,332		2,331,543		2,374,875		3.08		4.9	$	8,836,000

Exercisable as of July 31, 2019	17,501		2,125,730		2,143,231		2.74		4.5	$	8,469,000

Activity related to these warrants, which expire at various dates through March 2020, is summarized as follows:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, May 1, 2019	1,671,440		$	6.20	0.9	$	5,730,000
Granted	—		—		—	—
Exercised	—		—		—	—
Canceled	—		—		—	—
Expired	(1,667	)	4.80		—	—

Outstanding, July 31, 2019	1,669,773		$	5.66	0.6	$	1,355,000